Non-Fiction Books:

Innovations for Next-Generation Antibody-Drug Conjugates

Click to share your rating 0 ratings (0.0/5.0 average) Thanks for your vote!

Format:

Hardback
$441.00
Available from supplier

The item is brand new and in-stock with one of our preferred suppliers. The item will ship from a Mighty Ape warehouse within the timeframe shown.

Usually ships in 2-3 weeks
Free Delivery with Primate
Join Now

Free 14 day free trial, cancel anytime.

Buy Now, Pay Later with:

4 payments of $110.25 with Afterpay Learn more

6 weekly interest-free payments of $73.50 with Laybuy Learn more

Availability

Delivering to:

Estimated arrival:

  • Around 8-20 May using International Courier

Description

Antibody-drug conjugates (ADCs) stand at the verge of a transformation.  Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges.  This volume focuses on the next generation of ADCs and the innovations that will enable them.  The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies.  While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties.  However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing.  The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies.  These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.

Author Biography:

Marc Damelin is Senior Director, Biology at Mersana Therapeutics in Cambridge, Massachusetts. His group is responsible for the discovery of therapeutic ADCs enabled by Mersana's proprietary linker-payload-scaffold technologies. Prior, Marc spent 10 years at Pfizer Inc. in the Oncology Research Unit, where he led ADC discovery teams and ultimately oversaw the ADC portfolio. He received his Ph.D. in Biophysics from Harvard University and conducted postdoctoral research at Columbia University Medical School as a Fellow of the Damon Runyon Cancer Research Foundation. 
Release date NZ
June 11th, 2018
Audiences
  • Postgraduate, Research & Scholarly
  • Professional & Vocational
Contributor
  • Edited by Marc Damelin
Edition
1st ed. 2018
Illustrations
52 Illustrations, color; 18 Illustrations, black and white; VIII, 357 p. 70 illus., 52 illus. in color.
Pages
357
ISBN-13
9783319781532
Product ID
27639630

Customer reviews

Nobody has reviewed this product yet. You could be the first!

Write a Review

Marketplace listings

There are no Marketplace listings available for this product currently.
Already own it? Create a free listing and pay just 9% commission when it sells!

Sell Yours Here

Help & options

Filed under...